Senti Biosciences (SNTI)

Executive Summary

Senti Biosciences (NASDAQ: SNTI) is a clinical-stage biotechnology company leveraging its proprietary synthetic biology Gene Circuit platform to engineer 'smarter' cell therapies for oncology. The company's technology enables precise control over therapeutic cell activity, potentially improving efficacy and safety in solid and hematological malignancies. Senti's lead product, SENTI-202, is a Logic-gated CAR-NK cell therapy targeting CD33 and FLT3 for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), currently in a Phase 1 clinical trial (NCT06325748). Additionally, SENTI-301A, a CAR-T cell therapy for hepatocellular carcinoma (HCC), is in a Phase 1 study (NCT06652243). Both programs represent early-stage clinical efforts, and the company's valuation (~$30.5M) reflects the high-risk, high-reward nature of novel cell therapy development.

Upcoming Catalysts (preview)

• H2 2026Initial Phase 1 data readout for SENTI-202 in AML/MDS40% success
• 2027Phase 1 dose-escalation update for SENTI-301A in HCC35% success
• 2026Potential partnership or financing announcement to extend cash runway50% success